Ballal Rahul D. 4

What Happened

• Rahul D. Ballal, a director of Enliven Therapeutics (ELVN), received an award of 17,126 derivative shares (reported as $0.00 per share) on 2026-02-12. The filing classifies the transaction as an award/grant (code A) rather than an open-market purchase or sale. No cash was reported as paid in connection with the grant.

Key Details

• Transaction date: 2026-02-12; reported price: $0.00; total reported cash value: $0.
• Security type: derivative (award/option); filing indicates these are subject to vesting (see footnote).
• Vesting (Footnote F1): 100% of the shares subject to the option will vest on the earlier of (i) the first anniversary of the 2026 annual meeting of stockholders or (ii) the date of the 2027 annual meeting, provided Ballal continues as a non-employee director through the applicable vesting date.
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Filing date: 2026-02-17 (five days after the transaction date); filing appears to be late relative to the typical two-business-day Form 4 deadline.

Context

• This was a director compensation award (derivative/option grant), not an open-market buy or sale. Such grants are common for non-employee directors as part of board compensation and do not by themselves indicate immediate buying or selling of stock.
• Because the award vests in the future and was reported at $0, there was no immediate cash outlay or sale of shares at the time of the grant.